Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A study to find out about treatment side effects
More about this trial
To find out about the side effects people had, the team:
- interviewed people with cancer
- held focus groups with people with cancer
- interviewed healthcare professionals
The aim of this study was to develop a questionnaire to accurately reflect the side effects of targeted medicines. They also wanted the questionnaire to find out how people feel during treatment.
The study was open for people to join between 2012 and 2014. The team published the results in 2020 and 2021.
Summary of results
The researchers were able to develop a questionnaire. It accurately found out about the side effects of targeted drugs.
This was an international study run in 16 countries. A total of 316 patients and 86 healthcare professionals took part.
After the interviews and focus groups the team identified 209 side effects. They reduced this to 74 side effects.
They then tested this set by asking 102 patients from 7 countries to fill in the questionnaire. After this the team reduced it by a further 13 side effects.
The final questionnaire was a set of 61 side effects over 12 different categories.
The 2 most common side effects reported for these targeted medicines were:
- lack of energy
The team found that the interviews with the patients made the greatest contribution to developing the set.
The team concluded that they were able to develop a questionnaire. The questionnaire is useful in assessing new targeted treatments and their side effects.
More detailed information
There is more information about this research in the references below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
Developing Symptom Lists for People with Cancer Treated with Targeted Therapies
Samantha C. Sodergren and others
Targeted Oncology, 2021. Volume 16, issue 1, pages 95-107.
A patient’s perspective on the side effects of tyrosine kinase inhibitors in the treatment of advanced and metastatic gastrointestinal stromal tumors
Deborah van de Wal and others
Future Oncology, 2020. Volume 19, issue 4.
Where this information comes from
We have based this summary on the information in the articles above. These have been reviewed by independent specialists
How to join a clinical trial
Professor Colin Johnson
European Organisation for Research and Treatment of Cancer (EORTC)
EORTC Quality of Life Group
NIHR Clinical Research Network: Cancer
University Hospital Southampton NHS Foundation Trust